Gedeon Richter Plc. and Allergan plc (NYSE:AGN) today announced that nine posters showing additional scientific data and clinical study on the antipsychotic cariprazine, will be exhibited during the upcoming American Psychiatric Association (APA) annual meeting in Atlanta.
Dr. David Nicholson, president and executive vice president of Global R&D at Allergan, said that the abstracts that will be shown during the APA annual meeting underscore the safety and effectiveness of cariprazine and investigating its abilities to give extra therapeutic benefits for the treatment of the negative symptoms of schizophrenia and bipolar manic depression.
Come Monday, May 16th, Gedeon Richter and Allergan will present their data on Cariprazine under the following topics:
1) Safety for patients with Bipolar Mania or Schizophrenia and the cariprazine plasma concentration to efficacy relationship.
2) Cariprazine’s effectiveness on prime negative symptoms of patients with schizophrenia.
3) Effectiveness of cariprazine on cognitiveand social function symptoms in schizophrenia.
4) Early improvement as a predictor of response and remission of bipolar disorder – a pooled analysis of 3 randomized cariprazine trials.
5) Characterization of Population Pharmacokinetics of Cariprazine and Its Major Metabolites.
6) Effectiveness of cariprazine on bipolar manic depression – post hoc band-pass analyses of 2 randomized trials
7) Long term cariprazine treatment for the prevention of relapse in patients with schizophrenia: analysis of additional efficacy outcomes
Cariprazine is an oral atypical antipsychotic that is supposed to be taken once daily. The United States Food and Drug Administration approved cariprazine, marketed as VRAYLAR™, for the treatment of adults with mixed or manic episodes associated with bipolar disorder. Also, cariprazine is indicated for the treatment of schizophrenia in adults.
Details on the exact mechanism of action are unknown for the drug. However, it is believed to influence the functioning of neurotransmitters including serotonin and dopamine. Cariprazine’s effectiveness can be arbitrated through a combination of partial agonist activity at serotonin 5-HT1A and central dopamine D2 receptors and rival activity at serotonin 5-HT2A receptor.
